Exelixis | EXEL - Trade Debtors


Exelixis reported $311.3M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 139.44M 19.75M Sep/2025
Agios Pharmaceuticals USD 5.03M 43K Sep/2025
Amgen USD 8.49B 211M Sep/2025
AstraZeneca USD 17.56B 1.32B Sep/2025
Bayer EUR 14.91B 2.73B Sep/2025
BioMarin Pharmaceutical USD 790.27M 65.59M Sep/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Cytokinetics USD 1.81M 6.6M Sep/2025
Eisai JPY 224.06B 4.08B Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Exelixis USD 311.3M 17.42M Sep/2025
Genmab DKK 998M 199M Jun/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
Incyte USD 895.89M 53M Sep/2025
Ionis Pharmaceuticals USD 24.61M 27.97M Sep/2025
MacroGenics USD 69.23M 56.7M Sep/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 1.05B 589M Sep/2025
Neurocrine Biosciences USD 728M 132.3M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
Sanofi EUR 397M 186.13M Dec/2025
Takeda JPY 757.92B 55.68B Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Xencor USD 21.8M 25.75M Sep/2025